Similar articles

• The HOPE study and diabetes. Heart Outcomes Prevention Evaluation.

  Stubanus M, Endemann D, Fischereder M, Ittner KP, Krämer BK. Stubanus M, et al. Lancet. 2000 Apr 1;355(9210):1183; author reply 1183-4. doi: 10.1016/s0140-6736(05)72260-1. Lancet. 2000. PMID: 10791401 No abstract available.
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

  [No authors listed] [No authors listed] Lancet. 2000 Jan 22;355(9200):253-9. Lancet. 2000. PMID: 10675071 Clinical Trial.
• HOPE for all people with diabetes? Heart Outcomes Prevention Evaluation.

  Marshall SM. Marshall SM. Diabet Med. 2000 Sep;17 Suppl 2:9-10. doi: 10.1046/j.1464-5491.2000.00361-5.x. Diabet Med. 2000. PMID: 11048826 No abstract available.
• Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE.

  Gerstein HC. Gerstein HC. Diabetes Metab Res Rev. 2002 Sep-Oct;18 Suppl 3:S82-5. doi: 10.1002/dmrr.285. Diabetes Metab Res Rev. 2002. PMID: 12324991 Review.
• Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.

  Studney D. Studney D. Can J Cardiol. 2002 May;18 Suppl A:3A-6A. Can J Cardiol. 2002. PMID: 12045787 Review.